Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475667 | 1.00 | CHRM2 (0.44) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL475670 | 1.00 | CHRM2 (0.44) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL18815551 | 0.82 | SCN10A (0.40) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL18815550 | 0.82 | SCN10A (0.40) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL12900577 | 0.78 | SLC6A2 (0.40) | CHRNB2 | |
| SCHEMBL3657287 | 0.78 | NR1H4 (0.36) | CHRM5CHRM3CHRM1CYP1A2CYP2C9 | |
| SCHEMBL21163845 | 0.76 | CHRM5 (0.38) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL670851 | 0.74 | CHRM5 (0.37) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL13387580 | 0.74 | CHRM5 (0.37) | CHRM2CHRM5CHRM3CHRM4CHRM1 | |
| SCHEMBL670852 | 0.74 | CHRM5 (0.37) | CHRM2CHRM5CHRM3CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-9006276-B2 | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006276-B2 | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006276-B2 | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20130029966-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-8044079-B2 | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof | ABBOTT GMBH & CO. KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-8044079-B2 | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof | ABBOTT GMBH & CO. KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-20100273766-A1 | SUBSTITUTED OXINDOL DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273766-A1 | SUBSTITUTED OXINDOL DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| EP-1957480-A1 | SUBSTITUTED OXINDOL-DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063123-A1 | SUBSTITUTED OXINDOL-DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029966-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | AVPR2, AVPR1B, AVPR1A | CHRM2 462/4885CHRM5 484/4885CHRM3 815/4885 |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | AVPR2, AVPR1B, AVPR1A | CHRM2 462/4885CHRM5 484/4885CHRM3 815/4885 |
| US-20100273766-A1 | SUBSTITUTED OXINDOL DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | AVPR2, AVPR1B, AVPR1A | CHRM2 378/4885CHRM5 480/4885CHRM3 621/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | CHRM2 161/4885CHRM5 246/4885CHRM3 406/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | CHRM2 237/4885CHRM5 292/4885CHRM3 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.